Related Experiment Video
Updated: Apr 20, 2026
Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
Published on: December 15, 2017
Risk-based strategy for evaluating and controlling residual protein impurities in enzymatically synthesized calcium
Zhuyu Jin1, Qiaoqiao Huang1, Xiao Sun1
1Zhejiang Institute for Food and Drug Control, National Medical Products Administration Key Laboratory for Core Technology of Generic Drug Evaluation, Zhejiang Key Laboratory of Biopharmaceutical Contact Materials, Hangzhou, 310052, China.
Abstract:
Regulatory bodies (e.g., FDA, NMPA, EDQM) mandate control of residual protein impurities in enzymatically produced pharmaceuticals, yet a standardized, risk-informed methodology for their safety assessment is lacking. This study addresses this gap for calcium gluconate, a critical injectable API. We compared three techniques for target residual protein (GOD and CAT); ELISA uniquely achieved ppb-level detection, outperforming HPLC-MS and HPLC-FD (ppm-level). Crucially, the target enzymes constituted only ≈0.04% of the total residual protein, necessitating a multi-method approach (Kjeldahl, BCA, Bradford, AAA) to quantify the total burden at 192-269 ppm. Ultrafiltration-based profiling revealed >80% of residues were low molecular weight (<3 kDa), while the >3 kDa fraction represented the primary immunogenic risk. We therefore propose a novel, risk-based control strategy that integrates specific enzyme verification with total residual protein monitoring and advocates deducting the low-risk <3 kDa fraction. This refines the control target from >200 ppm to <50 ppm, providing a practical framework that links analytical detection to safety assessment for regulatory compliance and quality assurance of enzymatically synthesized drugs.
